Mesalamine (CAS 89-57-6) — formula C7H7NO3, molecular weight 153.14.
| CAS Number | 89-57-6 |
|---|---|
| Molecular Formula | C7H7NO3 |
| Molecular Weight | 153.14 |
| Melting Point | 260-280 °C |
| LogP | 1.2 |
| Applications | Uses: Used to make dyes and light-sensitive paper, Also used as a gastrointestinal anti-inflammatory drug, [Merck Index] A metabolite of the drug sulfasalazine, [REPROTOX], In manufacture of light-sensitive paper, azo and sulfur dyes, Treatment of ulcerative colitis (England), It is used orally, in a delay-release formulation, as a retention enema, and as a suppository., THERAP CAT: Anti-inflammatory (gastrointestinal), Synthetic Polymer MALDI Matrix Compounds, Use (kg) in Switzerland (2009): >5000, Use (kg, approx.) in Germany (2009): >75000, exact) in Germany (2009): 96794, Use (kg) in USA (2002): 136000, Consumption (g per capita) in Switzerland (2009): 0.64, Consumption (g per capita, approx.) in Germany (2009): 0.92, exact) in Germany (2009): 1.2, Consumption (g per capita) in the USA (2002): 0.48, Excretion rate: 0.1, Calculated removal (%): 92.1, Use Classification: Pharmaceuticals, Methods of Manufacturing: Preparation by reduction of m-nitrobenzoic acid with Zn dust and HCl, Formulations, Preparations: ... The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral mesalamine formulation is a once-daily MMX tablet that delivers the mesalamine to the colon, making it most useful in the treatment of ulcerative colitis. The MMX coating matrix and coating system begin dissolution in the final portion of the ileum. ..., Oral: Capsules, extended-release: 250 mg Pentasa, (Shire), 500 mg Pentasa, (Shire). Tablets, delayed-release: 400 mg Asacol, (Procter & Gamble). Rectal: Suppositories: 500 mg Canasa, (Axcan Scandipharm), 1 g Canasa, (Axcan Scandipharm). Suspension: 4 g, 60 mL Mesalamine Suspension Enema, (Clay-Park), Mesalamine Suspension Enema, (Teva), Rowasa Suspension Enema (with potassium metabisulfite), (Solvay)., Oral: Tablet Delayed Release: 1.2 g Lialda (Shire)., Consumption Patterns: (2000, England) 40, 421.72 kg, yr, General Manufacturing Information: Benzoic acid, 5-amino-2-hydroxy-: ACTIVE, One of the top 25 English prescription pharmaceuticals in 2000. |
Documented applications: Uses: Used to make dyes and light-sensitive paper, Also used as a gastrointestinal anti-inflammatory drug, [Merck Index] A metabolite of the drug sulfasalazine, [REPROTOX], In manufacture of light-sensitive paper, azo and sulfur dyes, Treatment of ulcerative colitis (England), It is used orally, in a delay-release formulation, as a retention enema, and as a suppository., THERAP CAT: Anti-inflammatory (gastrointestinal), Synthetic Polymer MALDI Matrix Compounds, Use (kg) in Switzerland (2009): >5000, Use (kg, approx.) in Germany (2009): >75000, exact) in Germany (2009): 96794, Use (kg) in USA (2002): 136000, Consumption (g per capita) in Switzerland (2009): 0.64, Consumption (g per capita, approx.) in Germany (2009): 0.92, exact) in Germany (2009): 1.2, Consumption (g per capita) in the USA (2002): 0.48, Excretion rate: 0.1, Calculated removal (%): 92.1, Use Classification: Pharmaceuticals, Methods of Manufacturing: Preparation by reduction of m-nitrobenzoic acid with Zn dust and HCl, Formulations, Preparations: ... The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral mesalamine formulation is a once-daily MMX tablet that delivers the mesalamine to the colon, making it most useful in the treatment of ulcerative colitis. The MMX coating matrix and coating system begin dissolution in the final portion of the ileum. ..., Oral: Capsules, extended-release: 250 mg Pentasa, (Shire), 500 mg Pentasa, (Shire). Tablets, delayed-release: 400 mg Asacol, (Procter & Gamble). Rectal: Suppositories: 500 mg Canasa, (Axcan Scandipharm), 1 g Canasa, (Axcan Scandipharm). Suspension: 4 g, 60 mL Mesalamine Suspension Enema, (Clay-Park), Mesalamine Suspension Enema, (Teva), Rowasa Suspension Enema (with potassium metabisulfite), (Solvay)., Oral: Tablet Delayed Release: 1.2 g Lialda (Shire)., Consumption Patterns: (2000, England) 40, 421.72 kg, yr, General Manufacturing Information: Benzoic acid, 5-amino-2-hydroxy-: ACTIVE, One of the top 25 English prescription pharmaceuticals in 2000..
Mesalamine is a chemical compound with CAS registry number 89-57-6 and molecular formula C7H7NO3 (molecular weight 153.14).
CAS number: 89-57-6
Its molecular formula C7H7NO3 comprises 7 C, 7 H, 1 N, 3 O atoms.
Also known as: Mesalamine · 美沙拉嗪 · 5-Aminosalicylic acid
The CAS registry number of Mesalamine is 89-57-6.
Molecular formula C7H7NO3, molecular weight 153.14.
It is also registered under: Mesalamine, 美沙拉嗪, 5-Aminosalicylic acid.
Recorded applications: Uses: Used to make dyes and light-sensitive paper, Also used as a gastrointestinal anti-inflammatory drug, [Merck Index] A metabolite of the drug sulfasalazine, [REPROTOX], In manufacture of light-sensitive paper, azo and sulfur dyes, Treatment of ulcerative colitis (England), It is used orally, in a delay-release formulation, as a retention enema, and as a suppository., THERAP CAT: Anti-inflammatory (gastrointestinal), Synthetic Polymer MALDI Matrix Compounds, Use (kg) in Switzerland (2009): >5000, Use (kg, approx.) in Germany (2009): >75000, exact) in Germany (2009): 96794, Use (kg) in USA (2002): 136000, Consumption (g per capita) in Switzerland (2009): 0.64, Consumption (g per capita, approx.) in Germany (2009): 0.92, exact) in Germany (2009): 1.2, Consumption (g per capita) in the USA (2002): 0.48, Excretion rate: 0.1, Calculated removal (%): 92.1, Use Classification: Pharmaceuticals, Methods of Manufacturing: Preparation by reduction of m-nitrobenzoic acid with Zn dust and HCl, Formulations, Preparations: ... The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral mesalamine formulation is a once-daily MMX tablet that delivers the mesalamine to the colon, making it most useful in the treatment of ulcerative colitis. The MMX coating matrix and coating system begin dissolution in the final portion of the ileum. ..., Oral: Capsules, extended-release: 250 mg Pentasa, (Shire), 500 mg Pentasa, (Shire). Tablets, delayed-release: 400 mg Asacol, (Procter & Gamble). Rectal: Suppositories: 500 mg Canasa, (Axcan Scandipharm), 1 g Canasa, (Axcan Scandipharm). Suspension: 4 g, 60 mL Mesalamine Suspension Enema, (Clay-Park), Mesalamine Suspension Enema, (Teva), Rowasa Suspension Enema (with potassium metabisulfite), (Solvay)., Oral: Tablet Delayed Release: 1.2 g Lialda (Shire)., Consumption Patterns: (2000, England) 40, 421.72 kg, yr, General Manufacturing Information: Benzoic acid, 5-amino-2-hydroxy-: ACTIVE, One of the top 25 English prescription pharmaceuticals in 2000..
Independent reference data for Mesalamine (CAS 89-57-6), compiled from public chemistry databases.
| CAS Registry Number | 89-57-6 |
|---|---|
| PubChem CID | 4075 |
| Molecular formula | C7H7NO3 |
| IUPAC name | 5-amino-2-hydroxybenzoic acid |
| UNII (FDA) | 4Q81I59GXC |
| Molecular Weight | 153.14 |
|---|---|
| XLogP3 | 1.3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 1 |
| Exact Mass | 153.042593085 |
| Monoisotopic Mass | 153.042593085 |
| Topological Polar Surface Area | 83.6 |
| Heavy Atom Count | 11 |
| Melting Point | 260-280 °C |
|---|---|
| Melting Point | 283 °C |
| Solubility | 0.84 |
| Solubility | 1.22e+01 g/L |
| Vapor Pressure | 0.00000006 [mmHg] |
| LogP | 1.2 |
| LogP | 0.48 |
5-Aminosalicylic acid; mesalamine; 89-57-6; Mesalazine; 5-Amino-2-hydroxybenzoic acid; 5-ASA; Fisalamine; Lialda; m-Aminosalicylic acid; Benzoic acid, 5-amino-2-hydroxy-; Mesalazina; sfRowasa; Apriso; p-Aminosalicylsaeure; Asacolitin; Mesalazinum
| GHS notification summary | 0.5% (1 / 195) |
|---|
| GHS notification summary | 0.5% (1 / 195) |
|---|---|
| Reported hazard statements | H315 (81.5%), H317 (44.1%), H319 (81.5%), H335 (81%), H412 (17.9%) |
This chemical does not meet GHS hazard criteria for 0.5% (1 of 195) of reports.
H315 (81.5%): Causes skin irritation [Warning Skin corrosion/irritation]
5-Aminosalicylic acid · CAS 89-57-6 · C7H7NO3. UNII 4Q81I59GXC. Melting Point: 260-280 °C; Melting Point: 283 °C; Solubility: 0.84.
Source: PubChem / Wikidata; the batch COA governs where values differ.
Supplier: Jinan Shenghe Chemical Co., Ltd.
中文页面: 5-氨基水杨酸